Clinical trials: Mycophenolate Mofetil, open to volunteers
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Methods of T Cell Depletion Trial (MoTD)
A multi-centre phase II trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based post-transplant cyclophosphamide.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- MoTD (NCT04888741)
- Testing
- Thymoglobulin, Cyclophosphamide, Cyclosporine
- Where
- 17 sites in United Kingdom
- Volunteers
- 400 people
- Sponsor
- University of Birmingham
Liver Transplant
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
This is a study to determine the safety, efficacy, and tolerability of taking away the anti-rejection medicine, tacrolimus, in liver transplant recipients in conjunction with everolimus monotherapy to preserve renal function.
- Trial name
- ELIMINATE (NCT06280950)
- Testing
- Everolimus, Tacrolimus (continued reduction), Tacrolimus (maintain 50% reduction)
- Where
- 12 sites in United States
- Volunteers
- 340 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hematological Malignancies, Graft-versus-Host Disease (GVHD)
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide in addition to two-drug graft-versus-host disease (GVHD) prophylaxis…
- Trial name
- PTCYGVHD (NCT06799195)
- Testing
- Attenuated-dose Cyclophosphamide, High-dose Cyclophosphamide, Sirolimus
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- University of Nebraska
Islet Transplantation
Islet Transplantation With Recipient T-Reg Cells or Deceased Donor Vertebral Bone Marrow Therapy
The goal of this clinical trial is to learn if patients who have brittle type 1 diabetes receiving an islet transplantation will have better control of their sugars if they also receive one of 2 types of immune cells along with…
- Trial name
- NCT05973734
- Testing
- Infusion of recipient T regulatory cell, Infusion of concomitant Donor Derived Vertebral Bone Marrow
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Stanford University
T Lymphoblastic Lymphoma
Allo-HSCT vs ASCT in Adult T-LBL
Autologous hematopoietic stem cell transplantation (ASCT) is the important consolidation for adult T-LBL. Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is also the important consolidation for adult T-LBL.
- Trial name
- TROPHY-NHL01 (NCT06741813)
- Testing
- ASCT, Allo-HSCT
- Volunteers
- 230 people
- Sponsor
- Peking University People's Hospital
Lupus Nephritis (LN)
Neutrophil Extracellular Traps and Lupus Nephritis
Lupus Nephritis is one of the most severe organ manifestations of systemic lupus erythematosus and represents a major cause of morbidity, chronic kidney disease, and long-term mortality.
- Trial name
- NCT07721857
- Testing
- Serum Neutrophil Extracellular Traps
- Volunteers
- 100 people
- Sponsor
- Assiut University
Acute Myeloid Leukemia (AML)
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
This open label, multicenter phase II/III study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60…
- Trial name
- BIG-1 (NCT02416388)
- Testing
- Idarubicin, Daunorubicin, HD Cytarabine
- Where
- 56 sites in France
- Volunteers
- 3,100 people
- Sponsor
- University Hospital, Angers
Hematologic Neoplasms
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Background: People with blood cancers often receive blood or bone marrow transplants. But even with these treatments, the risk of relapse is high.
- Trial name
- NCT05327023
- Testing
- donor lymphocyte infusion, Cyclophosphamide, Busulfan
- Where
- United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Systemic Sclerosis, Interstitial Lung Disease
Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease
The study includes adult patients with systemic sclerosis (SSc) with interstitial lung disease (ILD) to evaluate the efficacy and safety of nintedanib plus tocilizumab combination therapy compared to standard therapy…
- Trial name
- NINTOC-TU (NCT06297096)
- Testing
- Tocilizumab, Nintedanib, Standard therapy
- Where
- Poland
- Volunteers
- 86 people
- Sponsor
- National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
Lupus Nephritis, Chronic Kidney Diseases
SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease
Lupus nephritis (LN) is a common manifestation in patients with systemic lupus erythematosus (SLE), and is an important cause of acute kidney injury and chronic kidney disease (CKD).
- Trial name
- NCT06155604
- Testing
- Dapagliflozin 10mg Tab, Standard maintenance therapy
- Where
- Hong Kong
- Volunteers
- 150 people
- Sponsor
- The University of Hong Kong
Acute Myeloid Leukemia, Relapsed, Adult, Acute Myeloid Leukemia Refractory
Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)
The study is a Phase II clinical trial. Patients will receive intensity-modulated total marrow irradiation (TMI) at a dose of 9 Gray (Gy) with standard myeloablative fludarabine intravenous (IV) and targeted busulfan (FluBu4)…
- Conditions
- Acute Myeloid Leukemia, Relapsed, Adult, Acute Myeloid Leukemia Refractory, Chronic Myeloid Leukemia - Accelerated Phase, Myelodysplastic Syndromes
- Trial name
- BMT-13 (NCT06802315)
- Testing
- Intensity modulated total marrow irradiation, Cyclophosphamide (CTX), Fludarabine (Fludara)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Illinois Chicago
Heart Transplant
Belatacept in Heart Transplantation
This is a phase 2, prospective, multi-center, open-label clinical trial. Sixty-six (66) primary heart transplant recipients will be randomized (1:2) to receive either standard-of-care, tacrolimus-based immunosuppression, or a…
- Trial name
- NCT06478017
- Testing
- Belatacept, Tacrolimus, Mycophenolate Mofetil/Sodium
- Where
- 8 sites in United States
- Volunteers
- 66 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
A phase II trial of a reduced intensity conditioned (RIC) allogeneic hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy) for idiopathic severe aplastic anemia (SAA), paroxysmal nocturnal…
- Conditions
- Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Paroxysmal Nocturnal Hemoglobinuria
- Trial name
- NCT06412497
- Testing
- Rituximab, Rabbit ATG, Cyclophosphamide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lupus Nephritis
LUPKYNIS Drug-use Results Survey
The purpose of this study is to survey the safety of LUPKYNIS in patients with lupus nephritis under actual use conditions. In addition, information on efficacy will be collected.
- Trial name
- NCT07053891
- Testing
- Voclosporin (LUPKYNIS)
- Where
- Japan
- Volunteers
- 400 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Non Infectious Uveitis
Treatment FOr Corticosteroid Dependent UveitiS
FOCUS is the first prospective randomized study comparing standard of care (mycophenolate mofetil) to adalimumab in recently active non infectious uveitis (NIU) with steroid dependency.
- Trial name
- FOCUS (NCT06258915)
- Testing
- Adalimumab, Mycophenolate Mofetil
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
This phase I/II trial studies the side effects and best dose of a radioactive agent linked to an antibody (211At-BC8-B10) followed by donor stem cell transplant in treating patients with high-risk acute leukemia or…
- Conditions
- Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission, Chronic Myelomonocytic Leukemia
- Trial name
- NCT03670966
- Testing
- Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Cyclophosphamide, Total-Body Irradiation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Interstitial Lung Diseases
Efficacy and Safety of Golidocitinib for Rapidly Progressive Interstitial Lung Disease
The goal of this clinical trial is to learn whether adding the JAK inhibitor golidocitinib to standard corticosteroid therapy works to treat rapidly progressive interstitial lung disease (RP-ILD) in patients with acute worsening.
- Trial name
- NCT07737249
- Testing
- golidocitinib plus corticosteroid, non-JAK inhibitor immunosuppressant plus corticosteroid
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
IgA Nephropathy, Renal Insufficiency, Chronic
Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?
Global Burden of Diseases ranks chronic kidney disease (CKD) as the 12th leading cause of death, with an estimated 20% increase from 2010 to 2019.
- Conditions
- IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis, IGA Glomerulonephritis
- Trial name
- IA-GRACE-IgANT (NCT06676384)
- Testing
- Oral prednisolone and SoC, Gut-directed budesonide and SoC, Mycophenolate mofetil (MMF) and SoC
- Where
- 12 sites in India
- Volunteers
- 585 people
- Sponsor
- Christian Medical College, Vellore, India
Kidney Transplantation, Mycophenolate Mofetil
Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.
The purpose of this research is to determine the safety and efficacy of withdrawing MMF (Mycophenolate Mofetil) in kidney transplant recipients who are 55 years or older at the time of receiving a kidney transplant.
- Trial name
- RIOT (NCT06568549)
- Testing
- Mycophenolate Mofetil (MMF) Maintenance Group, Mycophenolate Mofetil (MMF) Withdrawal Group
- Where
- 3 sites in United States
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Hematologic Malignancy
HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT
This study is a single-center, non-randomized, single-arm pilot trial of omidubicel hematopoietic stem cell transplantation (HCT) for hematologic malignancies with myeloablative conditioning chemotherapy of physician's choice…
- Trial name
- NCT06731504
- Testing
- Abatacept
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Duke University